Eugene Sulkowski

6379550, Apr 30, 2002

Jul 24, 2000

09/624692

Kailash C. Chadha - Williamsville NY
Eugene Sulkowski - Buffalo NY
Elzbieta Kawinski - Orchard Park NY

Health Research, Inc. - Buffalo NY

B01D 1508

210635, 210656, 2101982, 435 723, 435 74

A method for capturing PSA and its molecular forms that may be in a fluid biological material including the steps of: preparing a chromatographic column by placing a thiophilic gel in a column where the thiophilic gel is formed from a water insoluble polymer where the surface of the gel is provided with thiophilic moieties that bind PSA in the presence of an adsorption liquid but that will release PSA upon elution with an eluting liquid, said thiophilic moieties comprising a two part structure wherein one part can be characterized as a hydrophilic electron acceptor and the other part is sulfur which acts as an electron donor; selecting a sample of a fluid biological material to be tested for PSA and its complexes; introducing the sample into the column; eluting the sample through the column; rinsing the column with adsorption liquid to remove materials that are unbound to the thiophilic gel; and capturing PSA and its complexes in eluted column fractions.

6692643, Feb 17, 2004

Apr 29, 2002

10/134235

Eugene Sulkowski - Buffalo NY
Kailash C. Chadha - Williamsville NY
Elzbieta Kawinski - Orchard Park NY

Health Research, Inc. - Buffalo NY

B01D 1508

210635, 210656, 2101982, 210222, 435 723, 435 74

A method for capturing PSA and its molecular forms that may be in a fluid biological material including the steps of: preparing a bed of magnetic beads by binding thiophilic ligands to the beds where the thiophilic ligands bind PSA and its complexes, said thiophilic ligands comprising a two part structure wherein one part can be characterized as a hy6drophilic electron acceptor and the other part is sulfur which acts as an electron donor; selecting a sample of a fluid biological material to be tested for PSA and its complexes; introducing the sample into the magnetic beads bound to thiophilic ligands so that PSA and its complexes bind to the thiophilic ligand; and magnetically removing the beads from unbound portions of the sample.

44850387, Nov 27, 1984

Oct 19, 1982

6/435295

Kailash C. Chadha - West Seneca NY
Eugene Sulkowski - Buffalo NY

Health Research (Roswell Park Division) - Buffalo NY

C07C10352
A61K 4502
C12P 2100
C07G 700

260112K

A process for the production and purification of human interferon derived from leukocyte of lymphoblastoid cell origin characterized by a sequence of steps involving chromatography of a solution of crude interferon on porous glass, utilizing three new classes of eluants for recovering the interferon bound to the porous glass, followed by cation exchange chromatography and finally chromatography on a hydrophobic sorbent material which process produces a final purified interferon in its natural form containing those protein components which are normally labile to low pH treatment along with those components which are pH stable. In one aspect, the improved method of purification also includes the optional molecular filtration of the crude interferon prior to initiating the purification process. In yet another embodiment, a new process for producing The invention described herein was made, in part, in the course of work under grant No. NOI-HB-2920 awarded by the National Heart, Lung And Blood Institute.

46580174, Apr 14, 1987

Feb 14, 1984

6/579994

Wlodzimierz E. Dembinski - Buffalo NY
Eugene Sulkowski - Buffalo NY

Health Research, Inc. (Roswell Park Division) - Buffalo NY

C07K 320
C07K 1526
A61K 4502

530351

A process for the large scale purification of human fibroblast interferon produced by human diploid fibroblasts under superinduction conditions characterized by a sequence of four chromatographic steps namely: (1) separation on CM-agarose; (2) separation on ConA-agarose; (3) separation on phenyl-agarose; and (4) elimination of ethylene glycol using CM-agarose which process yields a final overall recovery not less than 60% of the crude interferon starting material and having a specific activity not less than 1. times. 10. sup. 8 units per mg of protein.